Zymeworks Inc. Common Stock (ZYME) Stock Forecast & Price Target
Zymeworks Inc. Common Stock · NASDAQ
$23.01+0.15 (+0.68%)
15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 10 firms covering Zymeworks Inc. Common Stock, 10 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets range widely, $22.00 to $58.00 (about 2.6x), a sign of real disagreement on valuation. The average target of $38.40 sits 67% above the current $23.01. The rating mix has stayed broadly stable, with Buy-side ratings easing from 11 to 10 over recent months. On the fundamentals, the Street sees consensus EPS building from about $1.77 next quarter toward $0.28 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS10 ratings
Moderate Buy
Strong Buy00%
Buy10100%
Hold00%
Sell00%
Strong Sell00%
Based on 10 analysts giving stock ratings to Zymeworks Inc. Common Stock.
As of Jul, 10 of 10 firms rate ZYME a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
ZYME EPS & revenue forecast
EPS · NEXT QUARTER
$1.77
Range $-0.71 – $3.08 · 7 analysts · -781% YoY
Next period, 7 analysts expect Zymeworks Inc. Common Stock to earn $1.77 a share (range $-0.71 – $3.08), versus $-0.26 a year earlier. Full-year consensus is $1.31, growing to $0.28 the year after.
REVENUE · NEXT QUARTER
$194.3M
Range $4.2M – $268.2M · 7 analysts · +604% YoY
Revenue is expected to reach $194.3M (range $4.2M – $268.2M), +603.5% year-over-year. Full-year consensus is $311.7M, rising to $189.8M next year.
Top analysts covering Zymeworks Inc. Common Stock
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ZYME.
#1
Mayank Mamtani
B. Riley Securities · Rank #9
Buy
$40.00+73.8% to target
Overall win rate
53%
+ Follow
#2
Yigal Nochomovitz
Citigroup · Rank #131
Buy
$35.00+52.1% to target
Overall win rate
43%
+ Follow
#3
Andrew Berens
Leerink Partners · Rank #167
Buy
$58.00+152.0% to target
Overall win rate
50%
+ Follow
#4
RB
Robert Burns
HC Wainwright & Co. · Rank #195
Buy
$46.00+99.9% to target
Overall win rate
38%
+ Follow
#5
Reni J. Benjamin
JMP Securities · Rank #290
Buy
$32.00+39.0% to target
Overall win rate
33%
+ Follow
ZYME stock forecast FAQ
What is ZYME's average 12-month price target?+
The 10 analysts with a live target average $38.40 for Zymeworks Inc. Common Stock over the next 12 months, ranging from a $58.00 high to a $22.00 low.
Is ZYME stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 10 analyst ratings, 10 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for ZYME?+
The Street-high target is $58.00 (Leerink Partners), and the Street-low is $22.00 (Citigroup). The average of all 10 active targets is $38.40.
How many Wall Street analysts cover ZYME?+
10 analysts have an active rating on Zymeworks Inc. Common Stock, and 10 firms carry a live 12-month price target.
Who is the most accurate analyst covering ZYME?+
Among analysts who currently cover ZYME, Mayank Mamtani of B. Riley Securities has the strongest overall Quantellect track record (Rank #9). Their current call is Buy with a $40.00 target.
What is Zymeworks Inc. Common Stock's projected EPS for next quarter?+
The consensus estimate is $1.77 per share (range $-0.71 – $3.08) across 7 analysts. Full-year EPS is projected at $1.31, rising to $0.28 the following year.
How much revenue is Zymeworks Inc. Common Stock expected to report next quarter?+
Consensus revenue is $194.3M (range $4.2M – $268.2M). Full-year revenue is projected at $311.7M, growing to $189.8M next year.
Have analysts been upgrading or downgrading ZYME lately?+
As of Jul, 10 of 10 firms rate ZYME a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ZYME calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
